The FDA has approved atezolizumab combined with chemotherapy for treating stage III dMMR colon cancer, enhancing post-surgery treatment options.

Explore how biomarkers can predict BCG failure in high-risk bladder cancer, aiding in personalized treatment strategies.

A study suggests that a reduced dose of enfortumab vedotin may lower toxicity in older patients with urothelial carcinoma, ...

Explore a comparative study on ESR1 mutation testing using dPCR and NGS. Understand the strengths and applications of each ...

Learn how intelligent medical records enhance patient care, streamline workflows, and improve healthcare outcomes through ...

Explore the FDA fast track oncology drugs granted in September 2026, advancing treatments for various cancer types.

On Oct. 2, the U.S. Food and Drug Administration (FDA) approved pirtobrutinib (Jaypirca) for adults with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who ...

Recent headlines on leadership appointments, executive transitions, and notable recognitions spotlight the leaders helping to shape oncology research, patient care, and cancer organizations. MD ...

At WCLC 2026, three thoracic oncologists discuss first-line regimen selection, subcutaneous dosing, dermatologic prophylaxis, and dose modifications in EGFR-mutant NSCLC. Subcutaneous amivantamab has ...

Tarlatamab (Idella) provided meaningful intracranial activity without added safety concerns in a real-world analysis of patients with small cell lung cancer (SCLC) and brain metastases, including ...